Abstract
Cutaneous leishmaniasis (CL) is a diverse human disease caused by more than 20 Leishmania species transmitted by the bite of an infected sand fly. Diagnostic testing is recommended to confirm infection and determine the infecting species. Treatment decisions are complex and providers should consider infecting species, patient comorbidities, extent and location of lesions, and previous treatments. There is no single universal treatment for CL and some treatment can have toxicity. Treatment should be individualized and factors, such as self-healing nature of this infection, risk of metastatic complications (ie, mucosal leishmaniasis), and patient wishes, need to be included in individual risk-benefit treatment decisions.
| Original language | English |
|---|---|
| Pages (from-to) | 101-117 |
| Number of pages | 17 |
| Journal | Infectious Disease Clinics of North America |
| Volume | 33 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2019 |
Keywords
- Amphotericin
- Antimony
- Cutaneous leishmaniasis
- Leishmaniasis diagnostic testing
- Miltefosine
Fingerprint
Dive into the research topics of 'Cutaneous Leishmaniasis: Updates in Diagnosis and Management'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver